Efficacy of Bifidobacterium Animalis Subsp. Lactis and Lacticaseibacillus Rhamnosus Mixture in Children With ADHD
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Wecare Probiotics Co., Ltd.
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Clinical symptoms of ADHD
Study Overview
Brief Summary
This study investigates WecProB (Bifidobacterium animalis subsp. lactis and Lacticaseibacillus rhamnosus) to evaluate their potential to improve symptoms and safety in children with ADHD.
Detailed Description
Randomized groups were given a combination of probiotics or placebo in addition to treatment with a consistent dose (1.2 mg/kg/d) of conventional ADHD medication (atomoxetine). The total length of the study is 12 weeks, and at weeks 0, 4, 8 and 12 weeks of the trial, the clinical symptoms of ADHD will be assessed using a scale. Blood and stool samples will be collected at weeks 0 and 12, and psychological tests will be performed. Nucleic acid sequencing technology was used to identify bacterial species in feces, and high-throughput 16S rRNA sequences were quickly obtained by sequencing, and fecal metabolites were analyzed.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None (Participant)
Eligibility Criteria
- Ages
- 6 Years to 12 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of ADHD per DSM-5 criteria;
- •Age 6-12 years, gender-neutral;
- •IQ >70 on intelligence testing;
- •Participant/guardian comprehension and voluntary consent.
Exclusion Criteria
- •Those with a clear history of other serious neurological diseases, such as epilepsy, head trauma, encephalitis or meningitis, etc.;
- •Have taken antibiotics, probiotics or immunosuppressants within one month before starting the experiment;
- •Ongoing special diet, such as ketogenic diet, etc
- •BMI higher than the 90th percentile or lower than the 10th percentile for children of the same age and sex;
- •Those who have had symptoms of respiratory or digestive tract infection in the past month, such as fever, cough, diarrhea, etc.;
- •Those who have had inflammatory bowel disease in the past, such as ulcerative colitis, Crohn's disease, etc.;
Outcomes
Primary Outcomes
Clinical symptoms of ADHD
Time Frame: 56 days
The Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2), was employed to assess the executive functioning deficits commonly associated with ADHD in children. The BRIEF-2 scale ranges from a minimum of 0 to a maximum of 300 points. Higher scores on the BRIEF-2 indicate greater executive dysfunction, meaning that a higher score reflects worse outcomes.
Secondary Outcomes
No secondary outcomes reported